Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities Saint Herblain (France), April 26, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in ...
Valneva fait un point sur la recommandation d’utilisation de son vaccin contre le chikungunya par les autorités françaises Saint Herblain (France), le 26 avril 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’autorité publique de santé en France, la Haute Autorité de Santé (HAS), a mis à jour sa recommandation concernant l'utilisation du vaccin à dose unique de Valneva, IXCHIQ®, pour la prévention de la maladie causée par le virus du chikungunya (CHIKV) suite à une notification d'effets indésirables graves chez des personnes â...
Last Thursday during market hours, Lhyfe announced the confirmation of French State support for its 100MW Green Horizon project in Gonfreville-L'Orcher, close to Yara's ammonia facility near Le Havre (France). The public IPCEI support framework contract has been signed with BPI France for up to EUR
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers Saint Herblain (France), April 18, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current recommendation for IXCHI...
Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya Saint-Herblain (France), le 18 avril 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que lors de sa réunion ordinaire du 16 avril 2025, le comité consultatif américain sur les pratiques d'immunisation (ACIP) des centres de contrôle et de prévention des maladies (CDC) a mis à jour sa recommandation concernant l'utilisation du vaccin à dose unique de Valneva, IXCHIQ®, pour la prévention de la maladie...
Ipsos: A first quarter in line with expectations in a volatile environment A first quarter in line with expectations in a volatile environment Paris, April 17, 2025 - , one of the world's leading market research companies, achieved a revenue of 568.5 million euros in the first quarter 2025. Growth stands at 2.0%, including -1.8% organic, 2.9% from scope effect, and 0.9% from favourable currency effects. Ben Page, CEO of Ipsos, stated: “The first quarter results are in line with our expectations, which anticipate a gradual recovery in activity over the year considering the comparison basis...
Ipsos : Un 1er trimestre conforme aux attentes dans un environnement volatil Un 1er trimestre conforme aux attentes dans un environnement volatil Paris, 17 avril 2025 – , l’une des principales sociétés mondiales d’études de marché, a réalisé un chiffre d’affaires de 568,5 millions d’euros au premier trimestre 2025. La croissance s’établit à 2,0 %, dont -1,8 % en organique, 2,9 % d’effet de périmètre et 0,9% d’effets de change favorables. Ben Page, Directeur Général d’Ipsos, déclare : « Les résultats du premier trimestre sont en ligne avec nos attentes, qui tablent sur une reprise progres...
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ® Saint-Herblain (France), April 16, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, which will take place from April 21-24, 2025 at the Walter E. convention center in Washington, D.C. Under the leadership of the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior managers will participate in multiple events, including an impor...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.